Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Capital Expenditures (2018 - 2025)

Neurogene's Capital Expenditures history spans 5 years, with the latest figure at $76000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 34.48% year-over-year to $76000.0; the TTM value through Dec 2025 reached $76000.0, down 90.59%, while the annual FY2025 figure was $76000.0, 90.59% down from the prior year.
  • Capital Expenditures reached $76000.0 in Q4 2025 per NGNE's latest filing, up from -$128000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $780000.0 in Q1 2025 to a low of -$652000.0 in Q2 2025.
  • Average Capital Expenditures over 3 years is $109545.5, with a median of $111000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: soared 659.46% in 2024, then crashed 831.43% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $321000.0 in 2023, then crashed by 63.86% to $116000.0 in 2024, then plummeted by 34.48% to $76000.0 in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Capital Expenditures are $76000.0 (Q4 2025), -$128000.0 (Q3 2025), and -$652000.0 (Q2 2025).